If the merger of Pfizer’s off-patent drug unit and Mylan is approved, Mylan CEO Heather Bresch could earn more than $37.6 million in severance and vested benefits, according to The Pittsburgh Post ...

Shares of Pfizer fell more than 2% after the pharmaceutical giant announced that it would combine one of its units with Mylan. Upjohn, which is Pfizer's generic and off-patent branded drug division, ...

One company makes Xanax and Viagra. The other makes the popular EpiPen drug for people with allergies. Now they may be close to merging. One company makes Xanax and Viagra. The other makes the popular ...

Pfizer will merge its off-patent drug business with generic drugmaker Mylan, a move that would create a lower-priced medication powerhouse, according to The Wall Street Journal. The combined company ...

Pfizer and Mylan announced they are combining to create a global powerhouse in the low-price drug market. Pfizer said Monday it's offloading Upjohn, its portfolio of drugs that are no longer protected ...

Pfizer, the country’s largest drugmaker, is creating a hybrid new drug company by combining its off-patent branded drug business with the generic pharmaceutical company Mylan. Pfizer’s Upjohn, which ...

Mylan N.V. and Pfizer Inc. announced a definitive agreement to combine Mylan with Upjohn, Pfizer’s off-patent branded and generic established medicines business, creating a new global pharmaceutical ...

Sources are telling many reporters that Pfizer is close to a deal that would merge its off-patent drugs business with generic-drug maker Mylan to create a huge global entity making and marketing both ...

In separate consent judgments, Pfizer Inc. and Mylan Specialty LP will be required to submit new ad campaigns for EpiPen, a mobile device used to treat acute allergic reactions. Pfizer and Mylan must ...

NEW YORK, March 23 (Reuters) - Mylan Laboratories Inc. said on Friday it launched generic versions of Pfizer Inc.'s blockbuster Norvasc blood-pressure drug, a day after a federal court ruled a Pfizer ...

SAO PAULO (Reuters) - Teva Pharmaceutical Industries Ltd and Mylan NV have shown preliminary interest in a Brazilian generic drugmaking joint-venture in which Pfizer Inc has a 40 percent stake, two ...